IVIG (Gammagard Liquid 10%) for MMN — Evidence & Clinical Trials

Overview

Treatment Details

Mechanism of Action

Polyclonal IgG antibody pool; modulates immune response via mechanisms not fully understood. Only IVIG product FDA-approved specifically for MMN.

Dosing Notes

Loading dose ~2 g/kg over 2–5 days, then maintenance 1–2 g/kg every 2–8 weeks depending on response.

Treatment Type

pharmaceutical

Clinical Evidence

What the Evidence Shows

Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.

High: Supported by multiple robust studies or regulatory approval

Moderate: Supported by limited controlled studies or consistent case series

Low: Based on case reports, expert opinion, or early-phase data only

High ConfidenceSupported by multiple robust studies or regulatory approval

IVIG is the EFNS/PNS-recommended gold-standard first-line maintenance treatment for MMN.

Verified Jul 2026

Peer Reviewed

EFNS/PNS Guideline on management of multifocal motor neuropathy (joint task force report)

Published March 2006

View source ↗

Gammagard Liquid 10% is the only FDA-approved therapy specifically for MMN; ~80–90% of patients show improvement.

Verified Jul 2026

Fda Label

FDA approval of Gammagard Liquid 10% for multifocal motor neuropathy

View source ↗

Moderate ConfidenceSupported by limited controlled studies or consistent case series

Open-label phase 3 trial: sustained improvement in MRC sum score and grip strength at 52 weeks in 11/13 completers.

Verified Jul 2026

Clinical Trial Registry

Phase III Clinical Trial of NPB-01 (IVIG) Maintenance Therapy in Patients With MMN — NCT01827072

Published June 2015

View source ↗

Clinical Trials

Linked Trials1 trial

NCT01827072 ↗ clinicaltrials.gov

MRC sum score and hand-grip strength at week 52

Target enrollment: 13 participants

Phase 3

Completed

Started Apr 2013